Acorda Therapeutics amends Bylaws to enhance director nomination procedures and conform to Delaware law

Acorda Therapeutics, Inc.

Board adopted Amended and Restated Bylaws effective March 7, 2024.
Enhanced disclosure and procedural requirements for stockholder director nominations, including Rule 14a-19 compliance.
Updated provisions reflect recent amendments to Delaware General Corporation Law.
Includes clerical and conforming changes.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Acorda Therapeutics, Inc.: Adopted amended and restated bylaws effective immediately, enhancing disclosure and procedural requirements for stockholder director nominations and updating provisions to reflect Delaware law changes (effective 2024-03-07).

Change: bylaw amendment
Effective: 2024-03-07

Exact text from the filing

On March 7, 2024, the Board of Directors of Acorda Therapeutics, Inc. (the “Company”) adopted amendments to the Company’s Bylaws (the “Amended and Restated Bylaws”), which became effective immediately.

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0000950170-24-030816

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.